TY - JOUR AU - Ritchlin, C. T. AU - Colbert, R. A. AU - Gladman, D. D. PY - 2017 DA - 2017// TI - Psoriatic arthritis JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMra1505557 DO - 10.1056/NEJMra1505557 ID - Ritchlin2017 ER - TY - JOUR AU - Orbai, A. M. AU - Ogdie, A. PY - 2016 DA - 2016// TI - Patient-reported outcomes in psoriatic arthritis JO - Rheum Dis Clin N Am VL - 42 UR - https://doi.org/10.1016/j.rdc.2016.01.002 DO - 10.1016/j.rdc.2016.01.002 ID - Orbai2016 ER - TY - JOUR AU - Gossec, L. AU - Wit, M. AU - Kiltz, U. AU - Braun, J. AU - Kalyoncu, U. AU - Scrivo, R. AU - Maccarone, M. AU - Carton, L. AU - Otsa, K. AU - Sooaar, I. PY - 2014 DA - 2014// TI - A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2014-205207 DO - 10.1136/annrheumdis-2014-205207 ID - Gossec2014 ER - TY - JOUR AU - Finlay, A. Y. AU - Khan, G. K. PY - 1994 DA - 1994// TI - Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use JO - Clin Exp Dermatol VL - 19 UR - https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DO - 10.1111/j.1365-2230.1994.tb01167.x ID - Finlay1994 ER - TY - JOUR AU - Kampylafka, E. AU - d'Oliveira, I. AU - Linz, C. AU - Lerchen, V. AU - Stemmler, F. AU - Simon, D. AU - Englbrecht, M. AU - Sticherling, M. AU - Rech, J. AU - Kleyer, A. PY - 2018 DA - 2018// TI - Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study JO - Arthritis Res Ther VL - 20 UR - https://doi.org/10.1186/s13075-018-1653-5 DO - 10.1186/s13075-018-1653-5 ID - Kampylafka2018 ER - TY - JOUR AU - Kampylafka, E. AU - Simon, D. AU - d'Oliveira, I. AU - Linz, C. AU - Lerchen, V. AU - Englbrecht, M. AU - Rech, J. AU - Kleyer, A. AU - Sticherling, M. AU - Schett, G. PY - 2019 DA - 2019// TI - Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study JO - Arthritis Res Ther VL - 21 UR - https://doi.org/10.1186/s13075-019-1957-0 DO - 10.1186/s13075-019-1957-0 ID - Kampylafka2019 ER - TY - JOUR AU - Coates, L. C. AU - Gladman, D. D. AU - Nash, P. AU - FitzGerald, O. AU - Kavanaugh, A. AU - Kvien, T. K. AU - Gossec, L. AU - Strand, V. AU - Rasouliyan, L. AU - Pricop, L. PY - 2018 DA - 2018// TI - Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study JO - Arthritis Res Ther VL - 20 UR - https://doi.org/10.1186/s13075-018-1773-y DO - 10.1186/s13075-018-1773-y ID - Coates2018 ER - TY - JOUR AU - McInnes, I. B. AU - Mease, P. J. AU - Schett, G. AU - Kirkham, B. AU - Strand, V. AU - Williams, N. AU - Fox, T. AU - Pricop, L. AU - Jugl, S. M. AU - Gandhi, K. K. PY - 2018 DA - 2018// TI - Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study JO - Arthritis Res Ther VL - 20 UR - https://doi.org/10.1186/s13075-018-1610-3 DO - 10.1186/s13075-018-1610-3 ID - McInnes2018 ER - TY - JOUR AU - Strand, V. AU - Mease, P. AU - Gossec, L. AU - Elkayam, O. AU - Bosch, F. AU - Zuazo, J. AU - Pricop, L. AU - Mpofu, S. PY - 2017 DA - 2017// TI - Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2015-209055 DO - 10.1136/annrheumdis-2015-209055 ID - Strand2017 ER - TY - JOUR AU - Nash, P. PY - 2018 DA - 2018// TI - Psoriatic arthritis: novel targets add to a therapeutic renaissance JO - Lancet (London) VL - 391 UR - https://doi.org/10.1016/S0140-6736(18)31217-0 DO - 10.1016/S0140-6736(18)31217-0 ID - Nash2018 ER - TY - JOUR AU - Scher, J. U. AU - Ogdie, A. AU - Merola, J. F. AU - Ritchlin, C. PY - 2019 DA - 2019// TI - Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition JO - Nat Rev Rheumatol VL - 15 UR - https://doi.org/10.1038/s41584-019-0175-0 DO - 10.1038/s41584-019-0175-0 ID - Scher2019 ER - TY - JOUR AU - Elewski, B. E. AU - Puig, L. AU - Mordin, M. AU - Gilloteau, I. AU - Sherif, B. AU - Fox, T. AU - Gnanasakthy, A. AU - Papavassilis, C. AU - Strober, B. E. PY - 2017 DA - 2017// TI - Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab JO - J Dermatol Treat VL - 28 UR - https://doi.org/10.1080/09546634.2017.1294727 DO - 10.1080/09546634.2017.1294727 ID - Elewski2017 ER - TY - JOUR AU - Puig, L. AU - Augustin, M. AU - Blauvelt, A. AU - Gottlieb, A. B. AU - Vender, R. AU - Korman, N. J. AU - Thaci, D. AU - Zhao, Y. AU - Gilloteau, I. AU - Sherif, B. PY - 2018 DA - 2018// TI - Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study JO - J Am Acad Dermatol VL - 78 UR - https://doi.org/10.1016/j.jaad.2017.10.025 DO - 10.1016/j.jaad.2017.10.025 ID - Puig2018 ER - TY - JOUR AU - Coates, L. C. AU - Orbai, A. M. AU - Morita, A. AU - Benichou, O. AU - Kerr, L. AU - Adams, D. H. AU - Shuler, C. L. AU - Birt, J. AU - Helliwell, P. S. PY - 2018 DA - 2018// TI - Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity JO - BMC Rheumatol VL - 2 UR - https://doi.org/10.1186/s41927-018-0030-y DO - 10.1186/s41927-018-0030-y ID - Coates2018 ER - TY - JOUR AU - Mease, P. J. AU - Kavanaugh, A. AU - Coates, L. C. AU - McInnes, I. B. AU - Hojnik, M. AU - Zhang, Y. AU - Anderson, J. K. AU - Dorr, A. P. AU - Gladman, D. D. PY - 2017 DA - 2017// TI - Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial JO - RMD open VL - 3 UR - https://doi.org/10.1136/rmdopen-2016-000415 DO - 10.1136/rmdopen-2016-000415 ID - Mease2017 ER -